Intra-articular injection of hyaluronate and indomethacin in rabbits with antigen-induced arthritis.
Combined effects of hyaluronate and indomethacin in the treatment of rabbits with antigen-induced arthritis (AIA) were evaluated by assessing joint swelling, C-reactive protein (CRP) and prostaglandin E(2) (PGE(2)) levels with periodic intra-articular (ia) injections of hyaluronate alone (HA group) and with either a low or high concentration of indomethacin (LI-HA or HI-HA group). End-point analyses included matrix metalloproteinases-3 (MMP-3) activity and macroscopic and histological joint examinations. Results demonstrated that treatment in LI-HA and HI-HA groups resulted in statistically significant suppression of CRP, PGE(2, )and MMP-3 in comparison with those of HA group. Inhibition of serum CRP was only observed in LI-HA group. The order of serum MMP-3 inhibition was LI-HA>HI-HA>HA. Based on macroscopic and histological analyses of pannus formation, hyperplasia, inflammation, joint leakage and erosion, and loss of proteoglycan, the only statistically significant improvement was shown in LI-HA group compared to HA group and HI-HA group compared to control group.
Lo
Yow-Jen
YJ
College of Pharmacy, Taipei Medical University, Taipei, Taiwan, ROC.
Sheu
Ming-Thau
MT
Tsai
Wen-Chi
WC
Lin
Yun-Ho
YH
Li
Jau-Le
JL
Liang
Yu-Chih
YC
Chang
Chi-Ching
CC
Hsieh
Ming-Shium
MS
Chen
Chien-Ho
CH
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001169:Arthritis, Experimental / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D002097:C-Reactive Protein / Q000032:analysis; D015232:Dinoprostone / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006614:Hindlimb; D006820:Hyaluronic Acid / Q000008:administration & dosage*; D007213:Indomethacin / Q000494:pharmacology*; D007270:Injections, Intra-Articular; D007596:Joints / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D019278:Matrix Metalloproteinase 3 / Q000378:metabolism; D013264:Stifle / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D013583:Synovial Membrane / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D000894:Anti-Inflammatory Agents, Non-Steroidal; D006820:Hyaluronic Acid; D002097:C-Reactive Protein; D019278:Matrix Metalloproteinase 3; D015232:Dinoprostone; D007213:Indomethacin